What is Seaport Therapeutics 's change in AP?

Seaport Therapeutics (SPTX) reported change in AP of $2.78M in Q1 2026.

What does change in AP mean?

Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.

Seaport Therapeutics SPTX Change in AP

Change in AP at other companies

MYR GroupMYRG

$15.72M+301%

RepligenRGEN

$5.92M+188%

Galaxy Digital Inc. Class A Common StockGLXY

-$14.21M+5.7%

Versant Media Group, Inc. VSNT

$127M+485%

Loar HoldingsLOAR

$5.25M+172%

Kymera TherapeuticsKYMR

$8.82M+125%

Other financials

Income statement

See full

Operating income-$27.5M-70.2%

Net income-$25.4M-93.6%

EPS (diluted)-$10.34-83.0%

Balance sheet

See full

Cash & equivalents$52.9M—

Total debt$5.3M—

Total equity-$115.6M-220%

Total assets$227.7M—

Cash flow

See full

Operating cash flow-$20.2M+0.2%

CapEx--100%

Free cash flow-$20.2M+0.4%

Valuation

See full

Market cap$972.65M—

Enterprise value$925.08M—

Returns & leverage

See full

Debt / equity-0×—

Current ratio13.2×—

Where this comes from

Reported directly by Seaport Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableTrade.

The official record: Seaport Therapeutics ’s 10-Q, filed June 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Seaport Therapeutics 's change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Seaport Therapeutics 's change in AP?: Seaport Therapeutics (SPTX) reported change in AP of $2.78M in Q1 2026.
What does change in AP mean?: Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.